Member Info for SocialistB

@MrIndia

You might be onto something regarding not announcing the letter as they are presumably already working in the background, to avoid wasting time.

I'd be okay to save the cost of a RNS announcing the letter, just to then add another cost announcing 1st injection shortly afterwards.

I'd love the first injection to be given before Christmas and even better to be told before Christmas that HEMO CAR-T works.

I mean what a Christmas present for that PT and their family.

However, it raises the question about timing for the share price. (Because we do all want it to go up, I hope:-)

Is news best announced on this side of Christmas or after New year's Eve?

I guess, in the big picture it means nothing, as HEMO CAR-T is not what I see as the crown jewel, at least not from a money generating point of view.

Don't get me wrong HEMO CAR-T is going to be the game changer that puts Hemogenyx on the chart for everyone to see.

But CBR and the news we received last week ina RNS about the ability to modify white blood cells, now those are the ones that really can affect a lot of people.

And maybe more then once in their lifetime.

News regarding these products will come in 2025 I assume, and that ought to do something positive to the share price.

All in all, what is a couple of months between friends:-)

When can phase 1 start?

We are waiting for the letter. And while we are waiting, let's have a little bit of fun.

Do lets hear arguments for various scenarios.

When will it have it's maximum effect on the share price?

Before or after the consolidation?

Monday 9th of December 2024 it was announced in a RNS that:

95 % voted for the consolidation

92% voted for issuing up to 50% extra shares

That means that as of Friday 13th of December 2024 Hemogenyx will only have 3.504.539 shares circulating.

Or in other words, just slightly above 3.5 million shares.

The BOD are now allowed to issue up to 50% new shares over a period of time, I assume that to be 1 year.

Ergo, they can issue 1.752.269 shares.

Or in other words, somewhat less then 1.8 million shares but for the ease of it, let's just say 1.7 mililon shares.

The nominal value means nothing, other then that the BOD cannot issue shares at less then 1 pence a piece.

And a big reason for this whole exercise is to avoid issuing shares in the pence territory, so that won't happen.

The BOD can issue shares at :

Market price

Discounted price

Premium price

I think the best possible outcome for us all is shares issued at a significant premium.

But is that realistic at all?

Based on Prevails investments/exchange rate for services, I'd say yes, it is possible, at least in theory.

But, investors being investors, there might be a demand for warrents.

What I do not know is if the warrents that might be promised falls within the 1.7 million shares that can be issued or if it can be deferred to years away and fall within the 20% that usually is available for a BOD to issue in any given year.

Anyway, what sum should we expect to get for the 1.7 million shares the BOD are now allowed to issue?

10 million pounds? Equals 5.88 a share

20 million pounds? Equals 11.76 a share

30 million pounds? Equals 17.64 a share

50 million pounds? Equals 29.41 a share

I think the most likely way to get shares sold at the higher prices is to release them in tranches when we get successful results and big Pharma are queing up to be part of the game changing company.

I assume we will have to start out at the lower end my wishlist, maybe even with a discount to the market price.

But here's to hoping we get a completely different kettle of investors on board, that are willing to INVEST in the development of the product and play the long game.

Today's 0700 RNS

Site Initiation Visit Completed.

That's great news.

If we can then get the consolidation sorted today/ this week as well, then that would be fabulous.

If that can then be followed up with funding investments on good terms for the company and LTH, then there is every chance that the share price will rise when we get good news regarding first Patient being dosed and CBR.

Here's to hoping for consolidation

I know it's so easy to claim that there must be a conspiracy going on when things aren't going your way.

But is there really any other explanation that makes financial sense?

I cannot see that an RNS can be much more positive then what we got today, yet still there is only 131 trades taking place.

I think that low number after a fantastic RNS must be down to not making it onto the riser board.

Fantastic RNS and risers board usually equals increased interest, more buying and higher share price.

What we saw today was some significant sells and negativity on the board.

That does not make financial sense if you want to profit from a rising share price.

This kind of behaviour only makes sense if you have a financial interest in the share price falling or staying low.

Hence why I fear we are up against nefearious forces, that so far have been successful in lowering and keeping the share price low, making it hard to raise funding on good terms.

Question is, if there is a conspiracy to keep the share price low, will those people manage to derail the 400:1 conversation.

Right now I fear it is a real possibility.

And I do not know what can be done if they are successful.

Will even a funding RNS be able to move us?

I prey for the consolidation to go through and we get of the penny stock status.

@saint68

That's lack of an S does it make a significant difference?

What am I unaware off?

Now to the most important point.

I get what you are saying, but do you think we are likely to reach 4 pence with a string of good news?

As it has behaved, don't you think there is a big risk traders will take their 10-50 percent profit and that in turn will prevent a share price of 4 pence?

That is my fear.

@pumpky

In which case they have gotten about 10 percent discount to today's share price and I think that would be the smallest discount we have seen.

Most importantly we would then have 5 million in the coffer as per your scenario.

If funding is apoint concerning people, that should be gone and the share price react positively.

That is, if everything goes by the book

All quiet on the western front.

No news from the states, and why that might be a good thing.

I had expected a RNS regarding CBR this week, so Mr Sandler could really promote it at the conference and tell people about the new and most recent developments.

That has not happened and it raises the question why?

My guess ties in with CHRIS0123 suggestion earlier this morning about funding available when we are clinical and in the pound territory share price wise.

So please hold back on the news until the consolidation has happened.

After that, please tell us about

First injection

CBR news

Funding/JV etc

I think it is preferable for the share price to first get the news after the consolidation as I think it is a worry for people that are penny traders.

Lets wait with the explosive news until we appeal to a different bread of investors.

Any serios thoughts/arguments why not best to wait are most welcome.

Today is the day....

I just had to buy some shares as we are now producers.

I have done what I can to lower the supply and increase demand.

Lets face it, no matter how well Mr Day does his job, if there is not a bigger demand then supply then the share price won't move North.

So lets all chip in, shall we.

I for one is very happy with the explanations given yesterday by Mr Redmond and Dr Sandler as to why a consolidation is necessary.

More professional and seasoned investors and Pharmaceutical companies have expressed they would prefer not to invest in s penny stock.

And would love to see positive test results first.

Roll on with the trials, let's get a result.

And if it's not to much to ask, please let it be a positive one:-)

@BeardedDragon and Saint68

The obsticle is the penny share status, lets get into the pound territory.

I can see that the sentence ended up being incomplete, it should have said TO the BOD.

For me the following snippet makes it clear toe that the BOD must be convinced that investment/funding will follow once we are out of the penny share status.

"The Directors consider, having received feedback from some potential funders, that the "penny share" perception of the Company's shares deters most institutional and professional investors from participating in capital raises which the Company undertakes. This is relevant to both UK institutions and US-based life-sciences oriented institutional investors and potential partners"

The above is from the second RNS Friday.

An obsticle has been identified, now its up to us share holders to remove it.

We need to vote yes for the 400 consolidation.

It has been made clear the BOD that there is funding available if we move away from penny share status.

So lets do that.

Forge about the deferred shares, I see that as nothing but a paper exercise that needs to be undertaken to get us from penny stock pound territory.

Today's 2nd RNS was a bit of a shocker.

Consolidation of 400, that is huge.

But in a world of like for like, the new share price should be above 4 pounds.

And don't forget, if you held 1 % of the company before the consolidation, then you also do so afterwards.

However, as funding is sought from new investors you will be diluted.

But that should come as no surprise when investing at this stage in a research company without any income.

Why go for the high consolidation number of 400?

I think we might get listed on NYSE and as I recall, there is a minimum sum that the share must maintain to be eligible to be traded on NYSE.

I think it is worth paying attention to this sentence from today's RNS

"deters most institutional and professional investors from participating in capital raises which the Company undertakes. This is relevant to both UK institutions and US-based life-sciences oriented institutional investors and potential partners."

If we get listed on NYSE, that will be a game changer.

Lets face it, London stock exchange don't hack it for Hemogenyx.

Our share is traded and treated as an AIM share.

And we are not on AIM.

Lets go to NYSE, double listing would be fine with me.

@JustHereForHemo

I think you got a good point regarding the headroom.

I do not know what allowance was left, but am happy to take your word that it is gone (or as good as gone)

Shares cannot be issued ad libitum in this financial year and that fact can indeed be to our advantage as if someone did expect a selling into any rise, they now know that cannot happen, at least not with a significant amount of shares.

This morning's RNS felt like a kick in the b...., but for me personally rather that then a loan.

I would not like to have that responsibility hanging over my head, casting a shadow.

The lack of a loan, is in my view a bullet less that can be aimed at us.

Hemogenyx is funded for now, that is awesome.

I am chocked that HEMOGENYX are selling shares to an institutional investor at just 1 pence.

It's n the region of a 30% discount.

In my view, any proper investor would have paid the market price, so can't help but wonder if this is a spread betting institution.

But it does not have to be, either way, I see it as an indication that Hemogenyx was in a worse position then I thought.

Looking for the silver lining (because I have to do that)

1. Hemogenyx is still debt free, we do not have to fear the risks that comes with a loan.

2. I presume that the shares has not been sold to the shorters.

3. We now got the funds that the BOD deems to be absolutely necessary for the current situation.

4. There might still be funding coming our way when we get positive test results.

The big question for me is how on earth is the share price going to react to these news short term.

Will it fall to the issue level?

Will it start to rise as the most imminent funding issue has now been proven to be solved.

@Hulver, I very much agree with the possible explanations you give in your 0812 post, as to why we have not heard anything about the funding yet.

Personally, I'm always glad when a company does not release a RNS first thing Monday morning, as that always make me think it must be extra expensive as people have been working at Sunday rates to get it out first thing Monday morning.

No, better be frugal with the money spent on RNS' and spend it on the science, I say.

@GB1875 and Hulver

GB1875, I cannot put a finger on your post, everything you said is entirely possible timewise.

And what is one week more or less between friends:-)

Hulver, "CDX, CBR for cancers and CBR for viral infections are all quietly ticking along in the background", so true, so true.

And we can get funding news on any one of them at any given time.

However, I do think it is fair to expect funding news on HEMO CAR-T first, given the near proximity of trial start, but I am happy to be proven wrong.

But here is the thing, any news of any decent deal of funding on any of the products is good news and HEMOGENYX is a small agile company where it seems everybody is involved in each product on one level or another.

To me, that means, funding will ensure everyones paycheck and that they can work mainly on project X, and when time allows on the other projects as well.

If this is week 1, then the 3rd week ends Friday the 15th and the Site Initiation Visit (SIV) happen no later then that.

That's 2 weeks from now.

I expect news regarding funding before then.

Either we will be told we got enough in the coffers to dose the first couple of Patients and hopefully get proof of concept and big pharma are then forming a line to make a deal.

Or, we will get a grant or funding from someone to prove proof of concept, and maybe even more, but I would be happy with just enough to prove proof of concept, before asking for more money.

Lets just say, for arguments sake that it will cost between 100.000 - 150.000 per Patient to prove proff of concept, if that was the case, I think 500000 might be enough, which is a drop in the ocean for most big pharma or funds.

With about 2 weeks left before an possible explanation on how funding is sorted, are people in the know really willing to wait much longer before buying in?

Will the FOMO start before we get clarification or first afterwards.

Anyhow, there is every chance that it will start soon.

From today's RNS

"The Company has successfully completed the necessary contracts and budgeting preparations to advance HG-CT-1 into clinical testing."

To me it sounds like it is all sorted.

There might be an additional RNS at some point, regarding funding, but if not then it means HEMOGENYX has enough money to progress.

Now we just need possitive results for everyone involved, the Patients, the scientists shareholders.

@Islandgirl

Good find, thanks for sharing.

It would be awesome if we are getting support from the Focus Fund.

To me, it seems plausible that we tick all the boxes.